Provider Solutions

The Provider Solutions learning path is built to equip healthcare professionals with the knowledge and tools they need to deliver the highest standard of patient care using Natera’s cutting-edge genetic and molecular testing solutions. This comprehensive course introduces you to Natera’s entire portfolio—spanning oncology, women’s health, and organ health—while explaining how each solution integrates into clinical practice. You will learn when and why to order each test, including Signatera for molecular residual disease (MRD) detection, Altera for comprehensive genomic profiling, Empower for hereditary cancer risk assessment, Prospera for transplant rejection assessment, Renasight for kidney disease gene panels, Panorama for non-invasive prenatal testing (NIPT), Horizon for carrier screening, and Vistara for single-gene disorder screening. Each section breaks down the clinical indications, patient eligibility, ordering process, sample collection requirements, turnaround times, and reporting formats. Special attention is given to interpreting results—helping providers differentiate incidental findings from urgent results requiring immediate follow-up—and communicating them effectively to patients in a way that promotes understanding and shared decision-making. You will also gain insights into how Natera partners with providers to deliver training, ongoing education, and practice-building support, including sample workflows, EMR integration tips, and case studies demonstrating real-world clinical impact. This path includes microlearning videos, product deep dives, downloadable reference materials, and access to Natera’s AI chatbot for quick answers to common questions. We also highlight how your team can leverage sales and clinical liaison resources, email campaigns, and website links to make provider education part of your everyday workflow. By the end of this path, you will have a thorough understanding of how to integrate Natera’s solutions into your practice, streamline test ordering, improve patient outcomes, and stay ahead of emerging trends in genetic medicine.